ALLMedicine™ Hirsutism Center

May 19th, 2022 - Polycystic ovary syndrome (PCOS), is the most common endocrinological disorder that affects the reproductive aged women. In addition to causing problems such as menstrual irregularity, hirsutism, acne, it is also an important health problem that c...

May 14th, 2022 - The manifestations of Polycystic Ovary Syndrome (PCOS), including acne, hirsutism, obesity, uncertain fertility, etc., can make women anxious, worried, or even depressed with their appearance and body. However, little relevant research has been co...

May 14th, 2022 - Polycystic ovary syndrome (PCOS) is a global health problem associated with significant morbidity during reproductive age. Only a few published studies that address the clinical manifestations and phenotypic presentation of the disease have been c...

May 10th, 2022 - This study aimed to evaluate the Standardized Mean Difference (SMD) of insulin resistance parameters in women with IH, compared to healthy and polycystic ovary syndrome (PCOS) controls. PubMed, Scopus, Web of Sciences, and Embase were searched for...

May 10th, 2022 - Hyperandrogenic skin disorders, such as hirsutism, acne and alopecia, affect approximately 10-20% of women of reproductive age, reducing quality of life and causing psychological impairment. Spironolactone is a commonly used antiandrogen, especial...

Mar 10th, 2018 - To update the "Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline," published by the Endocrine Society in 2008. The participants include an Endocrine Society-appointed task force of seven...

Nov 9th, 2011 - Hirsutism, defined by the presence of excessive terminal hair in androgen-sensitive areas of the female body, is one of the most common disorders in women during reproductive age. We conducted a systematic review and critical assessment of the ava...

Feb 7th, 2008 - Our objective was to develop clinical practice guidelines for the evaluation and treatment of hirsutism in premenopausal women. The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society...

May 19th, 2022 - Polycystic ovary syndrome (PCOS), is the most common endocrinological disorder that affects the reproductive aged women. In addition to causing problems such as menstrual irregularity, hirsutism, acne, it is also an important health problem that c...

Apr 8th, 2022 - Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder among women in reproductive age with an estimated prevalence of 5% to 19.5%. It is a chronic complex syndrome with psychological (depression and anxiety), reproductive and meta...

Mar 29th, 2022 - Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, with an estimated prevalence of 6-15% of the general population worldwide. This heterogeneous syndrome has significant cardio-metabolic, reproduct...

Mar 21st, 2022 - 1.1 Study design This is a randomized double blind controlled. 1.2 Subject selection and exclusion Women with PCOS and IR will be recruited from the Department of Traditional Chinese Medicine in the first affiliated hospital of Guangzhou Medical U...

Jan 27th, 2022 - Consecutive patients coming to the Endocrinology and Diabetes Clinic of the S.Orsola hospital in Bologna with the suspicion of PCOS, during the study period, will be eligible to participate. In the screening phase, patients from the clinic conform...

May 17th, 2022 - BOSTON — Though hydroquinone, retinoids, steroids, and triple combination cream remain gold standards for the topical treatment of melasma, new synthetic and botanical topicals are emerging as adjuvant and alternative treatments, according to Nada...

Jan 28th, 2022 - Patients with relapsed or corticosteroid-resistant immune thrombocytopenia (ITP) had a 33% higher response rate and 50% increase in sustained responses with all-trans retinoic acid (ATRA) plus low-dose rituximab (Rituxan), Chinese investigators re...

Jan 4th, 2022 - The US Food and Drug Administration has approved levoketoconazole (Recorlev, Xeris Biopharma) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not possible or was not curative. Endogenous Cushin...

Dec 16th, 2021 - The FDA granted accelerated approval for the first drug to reduce proteinuria in primary immunoglobulin A (IgA) nephropathy, the agency announced on Wednesday. The delayed released budesonide (Tarpeyo) capsules are indicated to lower increased pro...

Oct 14th, 2021 - Certain oral contraceptives were associated with a lower risk for type 2 diabetes and prediabetes in women with polycystic ovary syndrome (PCOS), according to a retrospective, population-based study. An analysis of 64,051 women with PCOS found an ...